<?xml version="1.0" encoding="UTF-8"?>
<p content-type="flushleft">Since its discovery in 2012, cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV) have continued to emerge, with the current case count close to 2,500 cases, and a case fatality rate âˆ¼35% (
 <xref rid="r1" ref-type="bibr">1</xref>). This continuous emergence of MERS-CoV infections in Saudi Arabia and its ability to spread through human-to-human transmission has prompted the World Health Organization to include MERS on their list of emerging diseases likely to cause major epidemics and for which countermeasures are urgently needed (
 <xref rid="r2" ref-type="bibr">2</xref>). Through the Coalition for Epidemic Preparedness Innovations, MERS-CoV vaccines are going to advance through preclinical and clinical trials (
 <xref rid="r3" ref-type="bibr">3</xref>), but, despite the urgent need, a similar initiative does not exist for the development and clinical testing of antivirals effective against MERS-CoV.
</p>
